Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group.

Conroy, T

Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group. [electronic resource] - American journal of clinical oncology Apr 1994 - 97-102 p. digital

Publication Type: Journal Article

0277-3732

10.1097/00000421-199404000-00002 doi


Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Cisplatin--administration & dosage
Female
Humans
Indoles--adverse effects
Male
Middle Aged
Nausea--chemically induced
Neoplasms--drug therapy
Quinolizines--adverse effects
Serotonin Antagonists--therapeutic use
Treatment Outcome
Vomiting--chemically induced